Search

Your search keyword '"Mestroni, G"' showing total 404 results
Start Over Author "Mestroni, G"
404 results on '"Mestroni, G"'

2. Carbonyl derivatives of chloride-dimethyl sulfoxide-ruthenium(III) complexes: synthesis, crystal structure, and reactivity of (DMSO)(sub 2)Htrans-RuCl4(DMSO)(CO) and mer,cis-RuCl3(DMSO)(sub 2)(CO)

Author

Alessio, E., Bolle, M., Milani, B., Mestroni, G., Faleschini, P., Geremia, S., and Calligaris, M.

Subjects
Inorganic compounds -- Synthesis, Complex compounds -- Research, Coordination compounds -- Research, Crystals -- Structure, Chemistry
Abstract

The synthesis, spectroscopic characterization and crystal structure of (DMSO)(sub 2)Htrans-RuCl4(DMSO)(CO) and mer,cis-RuCl3(DMSO)(sub 2)(CO) are reported. These two compounds are the first examples of Ru(III) chloride-DMSO-carbonyl complexes. The S to O linkage isomerization of the DMSO ligand trans to it is induced by coordination of carbon monoxide.

Published
1995

3. Carbonyl derivatives of chloride-dimethyl sulfoxide-ruthenium(II) complexes: synthesis, structural characterization, and reactivity of Ru(CO)x(DMSO)(sub 4-x)Cl2 complexes (x = 1-3)

Author

Alessio, E., Milani, B., Bolle, M., Mestroni, G., Faleschini, P., Todone, F., Geremia, S., and Calligaris, M.

Subjects
Inorganic compounds -- Synthesis, Ruthenium -- Research, Complex compounds -- Spectra, Coordination compounds -- Research, Crystals -- Structure, Chemistry
Abstract

The reactions of cis- and trans-RuCl2(DMSO)(sub 4) with carbon monoxide is investigated. Cis-RuCl2(DMSO)(sub 4) reacts with CO at ambient pressure replacing one, two or three DMSO molecules. The reaction of trans-RuCl2(DMSO)(sub 4) with CO at room temperature and ambient pressure leads to the substitution of either one or two DMSO ligands. The coordination of CO activates the selective isomerization of the DMSO trans to it from S- to O-bonding. The crystal structure of these compounds have also been determined and is discussed.

Published
1995

9. Catalytic Processes

Author

Pez, G., Sacco, A., Bercaw, J. E., Brintzinger, H. H., Chiusoli, G. P., Felkin, H., Giongo, G. M., Langer, A., Mestroni, G., Meyer, T. J., Paiaro, G., Panunzi, A., Pino, P., Umani-Ronchi, A., Tsutsui, Minoru, editor, and Ugo, Renato, editor

Published
1977
Full Text
View/download PDF

10. Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma

Author

Coluccia, M., Sava, Gianni, Salerno, G., Bergamo, A., Pacor, Sabrina, Mestroni, G., Alessio, Enzo, Coluccia, M., Sava, Gianni, Salerno, G., Bergamo, A., Pacor, Sabrina, Mestroni, G., Alessio, Enzo, Coluccia, M, Sava, G, Salerno, G, Bergamo, A, Pacor, S, Mestroni, G, and Alessio, E

Subjects
Research Article
Abstract

The combinational treatment between the selective antimetastatic agent, sodium-trans-rutheniumtetrachloridedimethylsulfoxideimidazole, Na[trans-RuCl(4)(DMSO)Im], and the cytotoxic drug 5-fluorouracil (5-FU) on primary tumor growth and on the survival time of experimental tumors results in an effect significantly greater than that of each single agent used alone either with the solid metastasizing MCa mammary carcinoma of the CBA mouse or with the lymphocytic leukemia P388 and its platinum resistant P388/DDP subline. Thus the inorganic compound Na[trans-RuCl(4)(DMSO)Im], known for its potent and selective antimetastatic effects, positively interacts with the antitumor action of an organic anticancer agent such as 5-FU on both a solid metastasizing tumor and a tumor of lymphoproliferative type. In particular, the effects of the combinational treatment on the survival time of tumor bearing mice seem to be related to the selective antimetastatic activity of the ruthenium complex that joins the potent cytotoxicity of 5-FU for the tumor. Moreover, these data show that Na[trans-RuCl(4)(DMSO)Im] is almost as effective on the subline of P388 made resistant to cisplatin as it was on the parental line.

Published
1995

11. New anionic and neutral complexes of ruthenium (II) with nitrogen oxide

Author

MESTRONI G., ALESSIO, ENZO, SAVA, GIANNI, BERGAMO, ALBERTA, Mestroni, G., Alessio, Enzo, Sava, Gianni, and Bergamo, Alberta

Subjects
Ruthenium Drugs Tumours Therapy
Abstract

A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NNO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Published
2001

12. Leganti tridentati e loro complessi con metalli di transizione

Author

MILANI, Barbara, ZANGRANDO, ENNIO, MESTRONI G., BIANCHINI C., SOMMAZZI A., MANTOVANI G., MASI F., MELI A., SANTI R., Milani, Barbara, Mestroni, G., Bianchini, C., Sommazzi, A., Zangrando, Ennio, Mantovani, G., Masi, F., Meli, A., and Santi, R.

Published
2000

14. Fate of the antimetastatic ruthenium complex ImH[trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice

Author

Cocchietto M, Salerno G, Alessio E, Mestroni G, Gianni Sava, Cocchietto, M., Salerno, G., Alessio, Enzo, Mestroni, G., and Sava, Gianni

Subjects
NAMI-A, Animal studies, Pharmacokinetics, Antineoplastic Agents, Body Fluid Compartments, Models, Biological, Mice, Animal studie, Area Under Curve, Injections, Intravenous, Mice, Inbred CBA, Organometallic Compounds, Animals, Ruthenium Compounds, Dimethyl Sulfoxide, Kidney Diseases, Tissue Distribution, Neoplasm Metastasis
Abstract

The content of ruthenium in blood and different organs of healthy CBA mice was determined by AAS after single i.v. treatment of 200 mg kg-1 of NAMI-A, a new antimetastatic ruthenium compound. Ruthenium concentration in blood falls 5 min after i.v. treatment. In the kidney, ruthenium concentration is markedly higher than in any other analysed tissue. No ruthenium was detected in brains. Pharmacokinetic parameters for a mono- or a bi-compartment model are identifiable: t1/2 is 10.45 h vs 12.02 (t1/2 alpha 0.023 h + t1/2 beta 12 h) with Cltot of 1.60 ml*h-1 vs 1.59); Vd is 24.15 vs 27.48 ml and (model dependent) AUC is 689 vs 694 mg*L-1*h. AUC(0--infinity) calculated by noncompartmental method (linear trapezoidal rule) is 719.77 mg*L-1*h. NAMI-A is rapidly cleared from the blood compartment immediately after i.v. administration. Apparently, there is no differential accumulation of ruthenium in the lungs which might account for a selective antimetastatic effect caused by a cytotoxic concentration in this site, nor in any other specific organ examined.

Published
2000

18. Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole)

Author

Mestroni, G., Alessio, Enzo, Sessanta, O., Santi, A., Geremia, S., Bergamo, Alberta, Sava, Gianni, Boccarelli, A., Schettino, A., Coluccia, M., Mestroni, G., Alessio, Enzo, Sessanta, O., Santi, A., Geremia, S., Bergamo, Alberta, Sava, Gianni, Boccarelli, A., Schettino, A., and Coluccia, M.

Subjects
Experimental, Sulphoxide ruthenium complexes, Lymphoma, Antineoplastic, Sulphoxide ruthenium complexe
Published
1998

40. Mechanism of tumor inhibition by the metal complex trans-RuCl2(dimethylsulphoxide)4

Author

SAVA, GIANNI, PACOR, SABRINA, ALESSIO, ENZO, Bregant F., Ceschia V., Luxich E., Mestroni G., Sava, Gianni, Pacor, Sabrina, Bregant, F., Ceschia, V., Luxich, E., Alessio, Enzo, and Mestroni, G.

Subjects
Experimental tumours, Antitumour drugs, trans-Ruthenium dimethylsulfoxide, mechanism of action, Antitumour drug
Published
1990

Catalog

Books, media, physical & digital resources
See catalog results